Cancer vaccine trial tests immune system boost for rare lymphoma

NCT ID NCT01209871

Completed Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial tested a personalized DNA vaccine in 9 patients with a rare, slow-growing blood cancer called lymphoplasmacytic lymphoma. The vaccine was made from each patient's own cancer cells and designed to help the immune system recognize and attack the cancer. The main goal was to find the safest dose and check for side effects, with a secondary look at whether the vaccine sparked an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized DNA vaccine made from the patient's own cancer cells
What this could lead to: If it works, this could point toward a way to train the immune system to fight lymphoma without immediate chemotherapy.
What could go wrong: This is a very early, small phase 1 trial with only 9 participants. It is designed mainly to check safety, not yet to prove the vaccine works. Many early vaccines fail to show strong enough immune responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOPLASMACYTIC LYMPHOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.